Drug information provider Elsevier / Gold Standard, US, has announced its new Drug Class Overviews, making Clinical Pharmacology more valuable at the point of care.
Clinical Pharmacology Drug Class Overviews are now even more powerful for evaluating formulary decisions and therapeutic drug substitutions. Elsevier / Gold Standard has improved the speed and usability of the content through bulleted summaries and tables, highlighting a variety of critical areas in drug-interaction information.
The new Drug Class Overviews includes a summary in simple bullet format; Pharmacology/Mechanism of Action with key pharmacology and pharmacokinetics and tables to highlight differences; Therapeutic Use, highlighting place in therapy, alternatives within a class, and key clinical differences with labeled, off-label, and not recommended indications; Comparative Efficacy, highlighting randomized control trials for one or more indications; Adverse Reactions/Toxicities summarizes serious adverse events and toxicities; Drug Interactions, helping clinicians determine which drugs to use; and Safety Issues, highlighting all contraindications and indicates BBW’s, REMS, or MedGuides.
Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organisations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes.
